Clinical/Educational

In a study of 35 families, obese family members of patients undergoing bariatric surgery also showed a statistically significant weight loss.

Cohera Medical has announced that it has begun selling its lead product, TissuGlu® Surgical Adhesive, to hospitals and surgeons in three pilot territories in Germany.

AtriCure, Inc. a leader in cardiac surgical ablation systems has announced that it has closed enrollment in its DEEP AF feasibility trial, believing a staged approach will be more favourable for investigators in its forthcoming pivotal trial.

Uppsala University in Sweden adds to our understanding of bone healing and especially the potential place for BMP2 in this interesting academic press release from the institution.

Researchers report that ionized plasmas like those in neon lights and plasma TVs not only can sterilize water, but make it antimicrobial for as long as a week after treatment.

The Veith Vascular Symposium is taking place this week from November 16th to 20th in New York.

Heart rhythm records and calls about shocks from a registry of 14,475 patients with wearable defibrillators listed from 2007 through 2009 show 91.6 percent survived one or more episodes of ventricular fibrillation or ventricular tachycardia.

Abiomed announces Symphony™, a new synchronized minimally invasive implantable cardiac assist device.

American Heart Association Clinical Trial Report indicates that Radiofrequency ablation of target heart tissue shows better results than drug therapy in reducing atrial fibrillation.

In the week ahead, from 16 – 19 November 2011, the attention of health and medical care professionals from around the world will once again focus on Düsseldorf, as the world’s largest medical trade fair gets underway.

Results from the COBRA clinical trial presented at TCT2011 show restenosis rate significantly reduced in diabetics when Cryoplasty adopted in SFA Stenting.

Patients who are dependent on opioids for pain management before knee replacement surgery have much more difficulty recovering, a study recently published in theJournal of Bone and Joint Surgery (JBJS) has found.

Researchers claim Transapical TAVR is “unattractive from a health economic perspective.” compared with femoral approach.

Late breaking clinical trial results from testing of cangrelor, an investigational intravenous antiplatelet, showed patients can be “bridged” from the time that their physicians stop their oral antiplatelet drugs until they undergo cardiac surgery.

The Association of British Healthcare Industries (ABHI) is once again organising the UK Pavilion at MEDICA in partnership with UK Trade and Investment.

Update from TCT2011 sourced from an article by Medical Device Daily